Money

Found 74,652 articles

• Axonics® Announces Pricing of Public Offering of Common Stock - Aug 03, 2022

  8/3/2022

  Axonics, Inc., a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, announced that it priced its previously announced underwritten public offering of 1,750,000 shares of its common stock.

• Arcutis Biotherapeutics Announces Pricing of Public Offering of Common Stock

  8/3/2022

  Arcutis Biotherapeutics, Inc., an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, announced the pricing of its underwritten public offering of 7,500,000 shares of its common stock at a public offering price of $20.00 per share, representing a premium to the closing price of $19.50 per share on August 2, 2022.

• 

  With $122M, Startup IDRx Intends to Stop Cancer Mutations in their Tracks

  8/2/2022

  IDRx aims to create highly selective and aligned drug combinations to stop key tumor escape mechanisms that will support prolonged and durable responses to therapy. 

• Waters Corporation (NYSE: WAT) Reports Second Quarter 2022 Financial Results

  8/2/2022

  Sales of $714 million grew 5% as reported and 10% in constant currency Continued strong momentum as instrument sales grew 12% in constant currency, with double-digit growth across LC, MS and TA product lines Broad-based performance across all end-markets and major geographies, led by mid-teens growth in the U.S.

• KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Aug 02, 2022

  8/2/2022

  KalVista Pharmaceuticals, Inc., announced that the compensation committee of KalVista’s board of directors granted one newly-hired employee inducement options to purchase an aggregate of 7,000 shares of KalVista common stock on August 1, 2022 as inducement material to such employee entering into employment with KalVista.

• Eleven Therapeutics Announces $22 Million in Seed Funding

  8/2/2022

  Eleven Therapeutics announced today that it has raised a total of $22 million in seed funding.

• Aptose Reports Results for the Second Quarter 2022

  8/2/2022

  Aptose Biosciences Inc., a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, announced financial results for the three months ended June 30, 2022 and provided a corporate update.

• Acutus Medical Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Aug 02, 2022

  8/2/2022

  Acutus Medical, Inc., an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, granted equity awards on August 1, 2022 that were approved by the Compensation Committee of its Board of Directors under Company’s 2022 Inducement Equity Incentive Plan, as a material inducement to employment to 5 individuals hired by Acutus in July 2022.

• Utah Medical Products, Inc. Announces Quarterly Dividend - Aug 02, 2022

  8/2/2022

  Utah Medical Products, Inc. announces that its Board of Directors approved a quarterly cash dividend of twenty-nine cents per share of common stock payable on October 5, 2022 to shareholders of record at the close of business on September 16, 2022.

• Ligand Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Aug 02, 2022

  8/2/2022

  Ligand Pharmaceuticals Incorporated announced that effective August 1, 2022, Ligand’s Board of Directors approved the grant of non-qualified stock option awards to purchase an aggregate of 90,073 shares of its common stock, 5,000 restricted stock units and 4,000 performance stock units to six non-executive employees.

• Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Aug 02, 2022

  8/2/2022

  IVERIC bio, Inc. reported that on August 1, 2022, the Company granted equity-based awards pursuant to the Company’s 2019 Inducement Stock Incentive Plan to two newly-hired, non-executive employees.

• Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Aug 02, 2022

  8/2/2022

  Astria Therapeutics, Inc., a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological diseases, granted equity awards on August 1, 2022 under Astria’s 2022 Inducement Stock Incentive Plan.

• Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Aug 02, 2022

  8/2/2022

  Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced that the Company granted non-statutory stock options to new employees as inducement awards outside of the Company’s 2019 Stock Incentive Plan.

• Sironax Announces Closing of $200 Million Series B Financing

  8/2/2022

  Sironax today announced the completion of a $200 million Series B financing.

• Nordson Corporation Announces Earnings Release and Webcast for Third Quarter Fiscal Year 2022

  8/2/2022

  Nordson Corporation announced it will release third quarter fiscal year 2022 earnings on August 22, 2022 after the close of the market.

• Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Aug 02, 2022

  8/2/2022

  Akebia Therapeutics, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted six newly-hired employees options to purchase an aggregate of 26,000 shares of Akebia's common stock on July 29, 2022, as inducements material to each such employee entering into employment with Akebia.

• Semler Reports Second Quarter and First Half of 2022 Financial Results

  8/2/2022

  Semler Scientific, Inc., a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers, reported financial results for the three and six months ended June 30, 2022.

• Arcutis Biotherapeutics Announces Proposed Public Offering of Common Stock - Aug 02, 2022

  8/2/2022

  Arcutis Biotherapeutics, Inc., an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, announced the commencement of an underwritten public offering of $150.0 million of shares of its common stock.

• Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Aug 02, 2022

  8/2/2022

  Prothena Corporation plc announced that in connection with hiring a new employee, the compensation committee of the Company’s board of directors granted the individual hired by the Company an option to purchase 35,000 ordinary shares of the Company.

• IDEXX Laboratories Announces Second Quarter 2022 Results

  8/2/2022

  IDEXX Laboratories, Inc., a global leader in pet healthcare innovation, announced second quarter results, as well as an update on U.S. companion animal diagnostics trends.